COHANCE COHANCE.NS · Stock Open COHANCE in new tab

458.05 INR

Add to portfolio

P/E

87.00

EPS

4.67

P/B

3.98

ROE

3.84

Beta

0.57

Target Price

516.78 INR

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for COHANCE (COHANCE.NS)

Currency: INR

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

COHANCE Analysis (COHANCE.NS)

India Official Website Stock

Is COHANCE a good investment? COHANCE (COHANCE.NS) is currently trading at 458.05 INR. Market analysts have a consensus price target of 516.78 INR. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 87.00. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: COHANCE is expected to release its next earnings report on Aug. 7, 2026. The market consensus estimate for Forward EPS is 10.65.

Investor FAQ

Does COHANCE pay a dividend?

No, it does not currently pay a dividend.

What asset class is COHANCE?

COHANCE is classified as a Stock.

When is the next earnings date?

The next earnings date is projected to be Aug. 7, 2026. The company currently has a trailing EPS of 4.67.

Company Profile

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.

Trades

Dividend History paid per year (INR)

Historical Dividends

Year	Total Dividends
▸2022	11.00 INR
Oct. 2, 2022	6.0000
June 8, 2022	2.0000
March 10, 2022	3.0000
▸2021	2.00 INR
Sept. 30, 2021	1.0000
March 11, 2021	1.0000

Stock Splits

Split Date	Split Ratio to 1
Sept. 25, 2020	2.000000

Fundamentals

2026 © AllInvestView

Twitter YouTube Reddit Feature Requests Support Pricing Help

Support email: [email protected]

Terms of Service | Privacy Policy

Free Trackers · Dividend Apps · Tax Reporting · UK · Australia · Germany · Guides · Ticker Logos

Stock Directory · Financial Glossary · Portfolio Templates · Top Dividend Stocks · Investing in US · Investing in UK · Import Guides · Stock Comparison · Earnings Recaps

Data disclaimer: AIV (AllInvestView) assumes no liability for the information presented. Users are encouraged to exercise caution and carefully consider the accuracy, completeness, and relevance of the information provided.

It's important to remember that our website should complement your independent market research rather than replace it. The past performance of assets should not be regarded as a guarantee of future results. AllInvestView is not a registered investment advisor or broker/dealer, and the information presented here is for educational and informational purposes only. We value your trust and are committed to providing you with valuable market insights while emphasizing the importance of responsible decision-making in your investment journey.